Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13861 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Auke T Bergeman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Centre, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Diarylquinolines, Feasibility Studies, Electrocardiography, Leprosy. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Some anti‐mycobacterial drugs are known to cause QT interval prolongation, potentially leading to life‐threatening ventricular arrhythmia. However, the highest leprosy and tuberculosis burden occurs in settings where electrocardiographic monitoring is challenging. The feasibility and accuracy of alternative strategies, such as the use of automated measurements or a mobile electrocardiogram (mECG) device, have not been evaluated in this context. As part of the phase II randomized controlled BE‐PEOPLE trial evaluating the safety of bedaquiline‐enhanced post‐exposure prophylaxis (bedaquiline and rifampicin, BE‐PEP, versus rifampicin, SDR‐PEP) for leprosy, all participants had corrected QT intervals (QTc) measured at baseline and on the day after receiving post‐exposure prophylaxis. The accuracy of mECG measurements as well as automated 12L‐ECG measurements was evaluated. In total, 635 mECGs from 323 participants were recorded, of which 616 (97%) were of sufficient quality for QTc measurement. Mean manually read QTc on 12L‐ECG and mECG were 394 ± 19 and 385 ± 18 ms, respectively ( p < 0.001), with a strong correlation ( r = 0.793). The mean absolute QTc difference between both modalities was 11 ± 10 ms. Mean manual and automated 12L‐ECG QTc were 394 ± 19 and 409 ± 19 ms, respectively ( n = 636; p < 0.001), corresponding to moderate agreement ( r = 0.655). The use of a mECG device for QT interval monitoring was feasible and yielded a median absolute QTc error of 8 ms. Automated QTc measurements were less accurate, yielding longer QTc intervals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Heart Centre, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, The Netherlands.
- National Tuberculosis and Leprosy Control Program, Moroni, Comoros.
- Damien Foundation, Brussels, Belgium.
- Institute of Tropical Medicine, Antwerp, Belgium.
ORCID-Profile: Auke T Bergeman, Sofie M Braet, Harry van Loen, Christian van der Werf, Bouke C de Jong
Zitieren
APA
Bergeman, A. T., Nourdine, S., Piubello, A., Salim, Z., Braet, S. M., Baco, A., Grillone, S. H., Snijders, R., Hoof, C., Tsoumanis, A., van Loen, H., Assoumani, Y., Mzembaba, A., Ortuño-Gutiérrez, N., Hasker, E., van der Werf, C., & de Jong, B. C. (2024). Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment. Clinical and Translational Science. https://doi.org/10.1111/cts.13861
Vancouver
Bergeman AT, Nourdine S, Piubello A, Salim Z, Braet SM, Baco A, et al. Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment. Clinical and Translational Science. 2024. doi:10.1111/cts.13861
BibTeX
@article{Bergeman2024,
author = {Bergeman, Auke T and Nourdine, Said and Piubello, Alberto and Salim, Zahara and Braet, Sofie M and Baco, Abdallah and Grillone, Silahi H and Snijders, Rian and Hoof, Carolien and Tsoumanis, Achilleas and van Loen, Harry and Assoumani, Younoussa and Mzembaba, Aboubacar and Ortuño-Gutiérrez, Nimer and Hasker, Epco and van der Werf, Christian and de Jong, Bouke C},
title = {Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13861}
}
EUVIMED